Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients access to drugs for rare diseases. Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board as they relate to access for patients to rare disease medicines. Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries. Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines. Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Scientific Research and Experimental Development Tax Incentive Program as it pertains to research and development of treatments for rare disorders. Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients. Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders. Implementation of the Pharmacare Act as it relates to rare disease medicines. Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.
Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients access to drugs for rare diseases. Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board as they relate to access for patients to rare disease medicines Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries. Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines. Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Scientific Research and Experimental Development Tax Incentive Program as it pertains to research and development of treatments for rare disorders. Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders. Implementation of the Pharmacare Act as it relates to rare disease medicines. Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.